Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2006

01-03-2006 | Preclinical study

Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth

Authors: D.J. Britton, I.R. Hutcheson, J.M. Knowlden, D. Barrow, M. Giles, R.A. McClelland, J.M.W. Gee, R.I. Nicholson

Published in: Breast Cancer Research and Treatment | Issue 2/2006

Login to get access
Metadata
Title
Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth
Authors
D.J. Britton
I.R. Hutcheson
J.M. Knowlden
D. Barrow
M. Giles
R.A. McClelland
J.M.W. Gee
R.I. Nicholson
Publication date
01-03-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9070-2

Other articles of this Issue 2/2006

Breast Cancer Research and Treatment 2/2006 Go to the issue

Preclinical study

Neuregulins 1–4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast

Preclinical study

A possible regulatory role of 17β-estradiol and tamoxifen on glyoxalase I and glyoxalase II genes expression in MCF7 and BT20 human breast cancer cells

Review

From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies

Original Report

Use of raloxifene among women with a history of breast cancer

Preclinical study

High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model

Preclinical study

Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits